Literature DB >> 7592885

p80/85 cortactin associates with the Src SH2 domain and colocalizes with v-Src in transformed cells.

H Okamura1, M D Resh.   

Abstract

Expression of oncogenic variants of pp60src leads to dramatic changes in cytoskeletal organization characteristic of transformation. Activated Src associates with the cytoskeletal matrix, resulting in tyrosine phosphorylation of specific cytoskeletal substrates. We have previously shown that stable association of Src with the cytoskeletal matrix is mediated by the Src SH2 domain in a phosphotyrosine-dependent interaction. In this report, we demonstrate that one of the cytoskeletal binding partners of Src is p80/85 cortactin. The association was observed in lysates of transformed cells but was not seen in normal fibroblasts. The interaction could be reconstituted in vitro using transformed cell extracts and a glutathione S-transferase (GST) fusion protein containing the Src SH2 domain but not with GST-Src SH3 or with GST-Src SH2 containing a point mutation in the FLVRES sequence. Confocal microscopy revealed that cortactin redistributed and colocalized with v-Src and a Src SH3 deletion mutant in transformed cells. However, in cells expressing a Src SH2 deletion mutant, the redistribution of cortactin and colocalization with Src did not occur. Furthermore, biochemical fractionation of transformed cells indicated that a significant increase in cortactin distribution to the cytoskeletal fraction occurred, which correlated with a shift in the tyrosine-phosphorylated form of the protein. Cortactin fractionated from cells expressing kinase-defective or myristylation-defective Src mutants did not exhibit this shift. These data suggest a molecular mechanism by which tyrosine phosphorylation of cortactin and association with the Src SH2 domain influence the cytoskeletal reorganization induced in Src-transformed cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7592885     DOI: 10.1074/jbc.270.44.26613

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  37 in total

1.  Localization of human immunodeficiency virus type 1 Gag and Env at the plasma membrane by confocal imaging.

Authors:  L Hermida-Matsumoto; M D Resh
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

2.  Endocytosis as a mechanism for tyrosine kinase-dependent suppression of a voltage-gated potassium channel.

Authors:  Edmund Nesti; Brian Everill; Anthony D Morielli
Journal:  Mol Biol Cell       Date:  2004-06-23       Impact factor: 4.138

3.  Association of mouse actin-binding protein 1 (mAbp1/SH3P7), an Src kinase target, with dynamic regions of the cortical actin cytoskeleton in response to Rac1 activation.

Authors:  M M Kessels; A E Engqvist-Goldstein; D G Drubin
Journal:  Mol Biol Cell       Date:  2000-01       Impact factor: 4.138

4.  Palmitoylation of p59fyn is reversible and sufficient for plasma membrane association.

Authors:  A Wolven; H Okamura; Y Rosenblatt; M D Resh
Journal:  Mol Biol Cell       Date:  1997-06       Impact factor: 4.138

5.  A Drosophila model of multiple endocrine neoplasia type 2.

Authors:  Renee D Read; Paul J Goodfellow; Elaine R Mardis; Nancy Novak; Jon R Armstrong; Ross L Cagan
Journal:  Genetics       Date:  2005-06-18       Impact factor: 4.562

Review 6.  Cortactin in cell migration and cancer at a glance.

Authors:  Stacey M MacGrath; Anthony J Koleske
Journal:  J Cell Sci       Date:  2012-04-01       Impact factor: 5.285

7.  Src and Ras are involved in separate pathways in epithelial cell scattering.

Authors:  B Boyer; S Roche; M Denoyelle; J P Thiery
Journal:  EMBO J       Date:  1997-10-01       Impact factor: 11.598

8.  Src binds cortactin through an SH2 domain cystine-mediated linkage.

Authors:  Jason V Evans; Amanda G Ammer; John E Jett; Chris A Bolcato; Jason C Breaux; Karen H Martin; Mark V Culp; Peter M Gannett; Scott A Weed
Journal:  J Cell Sci       Date:  2012-10-24       Impact factor: 5.285

9.  Dynamin reduces Pyk2 Y402 phosphorylation and SRC binding in osteoclasts.

Authors:  Angela Bruzzaniti; Lynn Neff; Amanda Sandoval; Liping Du; William C Horne; Roland Baron
Journal:  Mol Cell Biol       Date:  2009-04-20       Impact factor: 4.272

Review 10.  Cortactin in tumor invasiveness.

Authors:  Alissa M Weaver
Journal:  Cancer Lett       Date:  2008-04-10       Impact factor: 8.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.